The diagnosis of c-kit negative GIST by PDGFRA staining: Clinical, pathological, and nuclear medicine perspective

Onkologie

Volumn 30, Issue 12, 2007, Pages 645-648

  Sevinc, Alper ^a   Camci, Celalettin ^a   Yilmaz, Mustafa ^a   Buyukhatipoglu, Hakan ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

GIST, c kit negative; Leiomyosarcoma; PDGFRA staining; PET CT

Indexed keywords

DOCETAXEL; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR; TOPOTECAN;

ABDOMINAL DISTENSION; ABDOMINAL RADIOGRAPHY; AGED; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; HOSPITAL ADMISSION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; TREATMENT RESPONSE;

AGED; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 37049030429     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109978     Document Type: Article

References (17)

1. Miettinen M, Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-1478.
2. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
3. Berman J, O'Leary TJ: Gastrointestinal stromal tumor workshop. Hum Pathol 2001;32:578-582.
4. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005;103:821-829.
5. Kalender ME, Sevinc A, Tutar E, Sirikci A, Camci C: Effect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neurofibromatosis type 1: a case report. World J Gastroenterol 2007;13:2629-2632.
6. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465.
7. Isaac JC, Willmore C, Holden JA, Layfield LJ: A c-kit-negative gastrointestinal stromal tumor with a platelet-derived growth factor receptor alpha mutation. Appl Immunohistochem Mol Morphol 2006;14:52-56.
8. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3:655-664.
9. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y: Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-667.
10. Yarden Y, Escobedo JA, Kuang WJ, Yang-Feng TL, Daniel TO, Tremble PM, Chen EY, Ando ME, Harkins RN, Francke U, Fried VA, Ullrich A, Williams LT: Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 1986;323:226-232.
11. George D: Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 2001;28(suppl 17):27-33.
12. Debiec-Rychter M, Wasag B, Stul M, de Wever I, van Oosterom A, Hagemeijer A, Sciot R: Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004;202:430-438.
13. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, Fletcher JA, Fletcher CD: Kit-negative gastrointestinal stromal tumors. Proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889-894.
14. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA: Kinase mutation and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
15. Zincirkeser S, Sevinc A, Kalender ME, Camci C: Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging. World J Gastroenterol 2007;13:2261-2262.
16. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C: We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-1764.
17. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759.